Deals
Lilly is named in a deal with Abridge and Nvidia, but no peptide or drug program details are available from the source.
Amazon and Novo Nordisk teamed up to deliver the Ozempic pill version on the same day in some areas. This deal makes it easier for people to get the weight-loss drug without waiting.
Same-day delivery makes Novo's oral semaglutide easier to get. That could help Novo win patients who want a pill instead of Lilly's shots.
Lilly is spending GLP-1 drug profits on buyouts. Terns was bought by Merck, not a peptide play.
Novo's CEO says the company wants to buy or license new drugs. This could mean fresh pipeline assets beyond its GLP-1 weight-loss franchise.
HYTN Innovations plans to split off its BPC-157 peptide drug business into a separate company. BPC-157 is a peptide being developed as a potential treatment for various conditions.
HYTN wants to split its BPC-157 drug work into its own company. This could help that peptide get more focus and funding for testing.
Novo's CEO says the company is hunting for more deals. That could mean new drug buys to help it catch up with Lilly in the weight-loss race.
Lilly is using its weight-loss drug cash to buy more companies. This builds out its pipeline beyond tirzepatide and locks in future growth.
Pfizer matched Novo Nordisk's offer to buy Metsera, a biotech company working on obesity drugs, as the two companies compete to acquire it. The bidding war shows how much pharmaceutical companies want to add new weight-loss treatments to their pipelines.
Pfizer and Novo are fighting to buy Metsera. The winner gets new obesity drugs to challenge Lilly and grow in the booming weight-loss market.
Hytn plans to separate its BPC-157 drug development business into its own company. BPC-157 is a peptide being studied as a potential treatment for various conditions.
BPC-157 is mostly sold today through gray-market peptide shops. A real drug developer working on it could push the peptide toward formal clinical testing.
HYTN is starting a new company focused on BPC-157, a peptide drug candidate, and plans to raise $1 million to fund it. The move splits BPC-157 development into its own separate business unit.
HYTN is spinning out its BPC-157 peptide work into a new company. The small $1M raise shows this is early-stage and far from a real drug.
A small company is splitting off its peptide drug unit into a separate business. Details are thin and the firm is not a major peptide player.